The Radioligand Therapy (RLT) Market is experiencing strong expansion as precision oncology becomes increasingly important in modern cancer treatment. The global market was valued at USD 8.14 billion in 2024 and is projected to grow from USD 8.906 billion in 2025 to USD 21.89 billion by 2035, registering a CAGR of 9.41% during the forecast period 2025–2035. North America led the market in 2024 with over 45.45% share, generating around USD 3.7 billion in revenue.

Radioligand therapy combines molecular targeting with therapeutic radiation to selectively reach cancer cells. This approach can help minimize exposure to surrounding healthy tissues while providing targeted treatment. Increasing adoption of precision oncology is therefore becoming a major factor supporting RLT demand across oncology centers.

The increasing global cancer burden is another important growth driver. According to the report, cancer caused approximately 9.7 million deaths globally in 2022, with around 20 million new cases. The growing need for advanced cancer treatment options is encouraging healthcare providers and pharmaceutical companies to invest in targeted therapies such as RLT.

Prostate cancer represents the largest indication segment, supported by the increasing use of PSMA-targeted therapies. Neuroendocrine tumors are also emerging as an important opportunity as SSTR-targeted treatments gain momentum. The PSMA segment is expected to increase from USD 2.5 billion in 2024 to USD 6.5 billion by 2035.

Technological advancements in radiochemistry, molecular imaging, and isotope development are further strengthening the market. Gallium-68 currently represents the largest isotope segment, while Lutetium-177 is experiencing rapid growth because of its therapeutic applications. The Lutetium-177 segment is projected to generate USD 8.0 billion by 2035.

Hospitals and clinics remain the leading end users because they possess specialized oncology infrastructure and trained medical professionals. Revenue from this segment is projected to rise from USD 3.24 billion in 2024 to USD 8.67 billion by 2035.

With continuing investment in precision medicine, radiopharmaceutical research, imaging technologies, and targeted oncology, the RLT market is expected to remain an important growth area within the global healthcare industry.